Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Payer Communications Safe Harbor Should Extend To Off-Label Uses – Industry

Executive Summary

US FDA should apply same regulatory protections to manufacturer communications with payers about unapproved uses that agency draft guidance provides to information exchanges about investigational products, biopharma companies say.

You may also be interested in...



US FDA Extends Payor Communications Safe Harbor To Off-Label Uses

Final guidance on drug manufacturer communications with payors adopts industry call to include exchanges about unapproved uses; they will not be considered evidence of intended use.

Pharmacoeconomic Communications To Payers Getting Multiple Pilots By Genentech

Bristol, Genentech execs describe how their companies are adapting to US FDA loosening some restrictions on how sponsors can talk about data that are 'related to' approved indications.

Trump Drug Pricing Plan May Include Rebate Pass-Through Push – Novartis CEO

Industry exec Jimenez hopes President Trump’s reform proposals, expected in next three months, will include measures to ensure manufacturer rebates are passed through to patients and encourage outcomes-based reimbursement contracts with payers.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel